Titre : Produits antisolaires

Produits antisolaires : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Produits antisolaires : Questions médicales les plus fréquentes", "headline": "Produits antisolaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Produits antisolaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-20", "dateModified": "2024-12-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Produits antisolaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Radioprotecteurs", "url": "https://recherchemedicale.com/mesh/D011837", "about": { "@type": "MedicalCondition", "name": "Radioprotecteurs", "code": { "@type": "MedicalCode", "code": "D011837", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.720.799.763" } } }, "about": { "@type": "MedicalCondition", "name": "Produits antisolaires", "alternateName": "Sunscreening Agents", "code": { "@type": "MedicalCode", "code": "D013473", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Henry W Lim", "url": "https://recherchemedicale.com/author/Henry%20W%20Lim", "affiliation": { "@type": "Organization", "name": "Department of Dermatology, Henry Ford Health Systems, Henry Ford Medical Center-New Center One, Detroit, Michigan, USA." } }, { "@type": "Person", "name": "Uli Osterwalder", "url": "https://recherchemedicale.com/author/Uli%20Osterwalder", "affiliation": { "@type": "Organization", "name": "Sun Protection Facilitator U.O. GmbH, Basel, Switzerland." } }, { "@type": "Person", "name": "Bernd Herzog", "url": "https://recherchemedicale.com/author/Bernd%20Herzog", "affiliation": { "@type": "Organization", "name": "BASF Grenzach GmbH, Koechlinstrasse 1, 79639 Grenzach-Wyhlen, Germany. bernd.herzog@basf.com." } }, { "@type": "Person", "name": "Leslie J Saunders", "url": "https://recherchemedicale.com/author/Leslie%20J%20Saunders", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, Simon Fraser University, Burnaby, British Columbia, Canada." } }, { "@type": "Person", "name": "John W Nichols", "url": "https://recherchemedicale.com/author/John%20W%20Nichols", "affiliation": { "@type": "Organization", "name": "US Environmental Protection Agency, Duluth, Minnesota." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Synthesis of [60]Fullerene Hybrids Endowed with Steroids and Monosaccharides: Theoretical Underpinning as Promising anti-SARS-CoV-2 Agents.", "datePublished": "2023-01-18", "url": "https://recherchemedicale.com/article/36721524", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ejoc.202201301" } }, { "@type": "ScholarlyArticle", "name": "Differential expression of lysine acetylation proteins in gastric cancer treated with a new antitumor agent bioactive peptide chelate selenium.", "datePublished": "2023-01-17", "url": "https://recherchemedicale.com/article/36684675", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.14384" } }, { "@type": "ScholarlyArticle", "name": "Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.", "datePublished": "2023-01-13", "url": "https://recherchemedicale.com/article/36642291", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cgh.2023.01.002" } }, { "@type": "ScholarlyArticle", "name": "Identification of Toxicity Forcing Agents from Individual Aliphatic and Aromatic Disinfection Byproducts Formed in Drinking Water: Implications and Limitations.", "datePublished": "2023-01-12", "url": "https://recherchemedicale.com/article/36633507", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.est.2c07629" } }, { "@type": "ScholarlyArticle", "name": "Safety outcomes of early initiation of antithrombotic agents within 24 h after intravenous alteplase at 0.6 mg/kg.", "datePublished": "2023-01-06", "url": "https://recherchemedicale.com/article/36657370", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2023.120546" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Recherchemedicale.com", "item": "https://recherchemedicale.com" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://recherchemedicale.com/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Utilisations spécialisées de produits chimiques", "item": "https://recherchemedicale.com/mesh/D020313" }, { "@type": "ListItem", "position": 4, "name": "Agents protecteurs", "item": "https://recherchemedicale.com/mesh/D020011" }, { "@type": "ListItem", "position": 5, "name": "Radioprotecteurs", "item": "https://recherchemedicale.com/mesh/D011837" }, { "@type": "ListItem", "position": 6, "name": "Produits antisolaires", "item": "https://recherchemedicale.com/mesh/D013473" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Produits antisolaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Produits antisolaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-02-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Produits antisolaires", "description": "Comment diagnostiquer une brûlure solaire ?\nQuels tests pour évaluer les dommages cutanés ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Produits antisolaires", "description": "Quels sont les symptômes d'une brûlure solaire ?\nPeut-on avoir des symptômes internes ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Produits antisolaires", "description": "Comment prévenir les brûlures solaires ?\nQuelle est l'importance de l'indice UV ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Produits antisolaires", "description": "Quel traitement pour une brûlure solaire ?\nQuand consulter un médecin après une brûlure ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Produits antisolaires", "description": "Quelles complications peuvent survenir ?\nComment les brûlures solaires affectent-elles la peau à long terme ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Produits antisolaires", "description": "Qui est le plus à risque de brûlures solaires ?\nQuel rôle joue l'altitude dans le risque de brûlures ?", "url": "https://recherchemedicale.com/mesh/D013473?page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une brûlure solaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Une brûlure solaire se diagnostique par l'apparition de rougeurs et de douleurs cutanées après exposition au soleil." } }, { "@type": "Question", "name": "Quels tests pour évaluer les dommages cutanés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des examens dermatologiques et des biopsies peuvent être réalisés pour évaluer les dommages cutanés." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une brûlure solaire ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent rougeur, douleur, gonflement et parfois cloques sur la peau." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes internes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes systémiques comme des frissons ou de la fièvre peuvent survenir dans les cas graves." } }, { "@type": "Question", "name": "Comment prévenir les brûlures solaires ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Utilisez des produits antisolaires, portez des vêtements protecteurs et évitez le soleil aux heures critiques." } }, { "@type": "Question", "name": "Quelle est l'importance de l'indice UV ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "L'indice UV informe sur l'intensité des rayons UV, aidant à planifier les activités extérieures en toute sécurité." } }, { "@type": "Question", "name": "Quel traitement pour une brûlure solaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut des compresses froides, des crèmes apaisantes et des anti-inflammatoires." } }, { "@type": "Question", "name": "Quand consulter un médecin après une brûlure ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si la brûlure est étendue, si des cloques se forment ou si des symptômes graves apparaissent." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections cutanées, des cicatrices et un risque accru de cancer de la peau." } }, { "@type": "Question", "name": "Comment les brûlures solaires affectent-elles la peau à long terme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les brûlures solaires répétées peuvent entraîner un vieillissement prématuré et des lésions cutanées chroniques." } }, { "@type": "Question", "name": "Qui est le plus à risque de brûlures solaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes à peau claire, les enfants et celles ayant des antécédents de brûlures sont plus à risque." } }, { "@type": "Question", "name": "Quel rôle joue l'altitude dans le risque de brûlures ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "À haute altitude, l'exposition aux UV est plus intense, augmentant le risque de brûlures solaires." } } ] } ] }

Sources (10000 au total)

Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.

Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis factor (TNF)-α antagonists vs n... We conducted a multicenter retrospective cohort study of patients with IBD and either active cancer (cohort A) or recent prior cancer (within ≤5 years; cohort B) who were treated with TNFα antagonists... In cohort A, of 125 patients (483.8 person-years of follow-up evaluation) with active cancer (age, 54 ± 15 y, 75% solid-organ malignancy), 10 of 55 (incidence rate [IR] per 100 py, 4.4) and 9 of 40 (I... In patients with IBD with active or recent cancer, TNFα antagonists and non-TNF biologics have comparable safety. The choice of biologic should be dictated by IBD disease severity in collaboration wit...

Safety outcomes of early initiation of antithrombotic agents within 24 h after intravenous alteplase at 0.6 mg/kg.

We examined outcome of acute ischemic stroke (AIS) with administration of antithrombotics within 24 h after intravenous low-dose alteplase.... Consecutive AIS patients who were treated with intravenous alteplase at 0.6 mg/kg from 2005 to 2021 were retrospectively included in our single-center registry. Patients were classified into two group... Of 1111 patients (women, 426; median age, 76 [interquartile range, 69-83] years; median NIHSS score, 11 [6-19]; cardioembolism, 580 [52.2%]), early initiation group comprised 58 patients (22; 72 [65-8... Early initiation of antithrombotics after intravenous alteplase at 0.6 mg/kg did not increase the rate of sICH or death within 3 months and may be used with caution in patients with advanced neurologi...

Potential Therapeutic Agents on Alzheimer's Disease through Molecular Docking and Molecular Dynamics Simulation Study of Plant-Based Compounds.

Globally Alzheimer's disease (AD) is a highly complex, heterogeneous, and multifactorial neurological disease. AD is categorized clinically through a steady loss in memory and progressive decline of c...